On August 5, 2019, Sigurdur Olafsson resigned from the Board of Directors of Pfenex Inc. effective immediately. Mr. Olafsson's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies, or practices. On August 7, 2019, the Board appointed Lorianne Masuoka, to Board. Dr. Masuoka will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2021. In addition, Dr. Masuoka was appointed to serve as a member of compensation committee. Lorianne Masuoka, has served as Chief Medical Officer of Marinus Pharmaceuticals Inc. since 2017. Dr. Masuoka has also served as a Clinical Development Consultant of Masuoka Consulting since 2011. From 2015 to 2017, she served as Chief Medical Officer of InVivo Therapeutics Holding Corp.